CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. In the completed Phase 3 study, CEL-SCI studied patients who were newly diagnosed with locally advanced primary squamous cell carcinoma of the head and neck with the investigational product Multikine administered first, before they received the standard of care, which involved surgery followed by either radiation or chemoradiation. The Phase 3 study enrolled 928 patients. Our approach is unique because most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed.
After analyzing data from the Phase 3 study, we have better defined the target population for Multikine, which is locally advanced primary head and neck cancer patients with no lymph node involvement and with low PD-L1 tumor expression. In the Phase 3 study, we observed statistically significant survival in this target population, showing that Multikine cut the risk of death in half at five years vs control.
Multikine (Leukocyte Interleukin, Injection) received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. Multikine is the trademark we have registered for this investigational therapy, and this proprietary name is subject to review by the FDA in connection with our future anticipated regulatory submission for approval.
Company Details
- Employees
- 46
- Founded
- -
- Address
- 8229 Boone Blvd, Vienna,virginia 22182,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.cel-sci.com/
- Keywords
- New York.
- HQ
- Vienna, Virginia
Cel-Sci Corporation Questions
Cel-Sci Corporation's website is http://www.cel-sci.com/
Cel-Sci Corporation's LinkedIn profile is https://www.linkedin.com/company/cel-sci-corporation
Cel-Sci Corporation has
46 employees.
View email and phone details for 46
employees at Cel-Sci Corporation.
Cel-Sci Corporation's industry is
Biotechnology Research
Cel-Sci Corporation's top competitors are
Thinkequity Llc,
Os Therapies,
Emergent Biosolutions,
Casi Pharmaceuticals, Inc.,
Bora Pharmaceuticals,
A-Bio,
Health Gorilla,
Astrazeneca,
Nanthealth,
Benitec Biopharma Inc..
Cel-Sci Corporation's categories are Biotechnology Research
Cel-Sci Corporation's founding year is 1983
